Brinedew

Info to rewrite the wiki on AP: User 12:00 PM

sanity check: “in literature, the definition of antagonistic pleiotropy has drifted to mean “any accumulating tradeoff ever”. The original definition Was meant to specifically single out sign flipping adaptations, those that are positive in young age and negative in old age Like the horns of a ram that if grown too large will pierce its own skull and kill him. Nowadays though the word antagonistic pleotropy means any adaptation with ramping costs over time even if the net sign never flips into the negative, like telomeres. Remove horns from an old drum and it will live many more years. Extend all telomeres of an old person and they will soon die of cancer”. name names

Sanity-check verdict: The core conceptual critique is sharp and very real—several prominent gerontologists have made nearly the exact same objection. However, the quote overstates the historical purity of the “original definition,” oversimplifies the ram-horn example, and makes an empirically overconfident claim about extending telomeres.

1. Did the “original definition” specifically mean sign-flipping adaptations?

Partly yes, partly no—it depends on whether you cite George Williams (1957) or Michael Rose (1982).

  • Where the quote is right (Williams 1957): George C. Williams did not actually use the phrase “antagonistic pleiotropy” in his landmark 1957 paper (Evolution). He proposed pleiotropic genes “that have opposite effects on fitness at different ages, or, more accurately, in different somatic environments.” Tellingly, his own hypothetical example was a clean sign-flipper: an allele that accelerates bone calcification during juvenile development, then continues depositing calcium into artery walls in adulthood (arteriosclerosis). Once growth stops, that late-life calcification is purely harmful—shutting it off in old age would be a pure win.
  • Where the quote overreaches (Rose 1982): The phrase “antagonistic pleiotropy” was actually coined 25 years later by Michael R. Rose (1982) (Heredity). From day one, Rose defined it in population-genetic terms as any allele with opposing effects on two different fitness components (producing a negative genetic correlation, e.g., boosting early fecundity at the expense of late survival). It did not strictly require a single trait’s instantaneous survival value to flip from positive to negative in old age.

In formal evolutionary genetics, the distinction the quote is grasping for—whether an effect literally reverses sign across contexts/ages vs. merely changes magnitude or trades off between domains—is often separated as sign pleiotropy vs. magnitude pleiotropy (e.g., Susanna Remold, 2012), while Annalise Paaby & Matthew Rockman (2013) (Trends in Genetics) warned that biologists routinely conflate molecular-gene pleiotropy, developmental pleiotropy, and selectional pleiotropy.

2. Has the literature drifted to “any accumulating tradeoff ever”? (Naming names)

Yes. In aging biology, “antagonistic pleiotropy” (AP) has widened into a giant catch-all label covering continuous energy-allocation compromises, ongoing cancer-vs.-regeneration constraints, and lifelong cumulative damage.

Who broadened AP to include ramping/ongoing tradeoffs and telomeres:

  • Thomas Kirkwood & Michael Rose (1991) (and Kirkwood & Holliday, 1979): Folded Kirkwood’s Disposable Soma Theory—continuous metabolic resource allocation between reproduction and somatic maintenance, which produces lifelong accumulating damage—into AP as a “special case” or physiological mechanism (though Kirkwood, 2017 later walked this back, noting you have to invert maintenance-gene action for it to cleanly fit AP).
  • Judith Campisi (2001, 2003, 2013): The biggest driver of calling cellular senescence (and telomere-driven replicative arrest) “a classic example of antagonistic pleiotropy”—tumor-suppressive in youth, but promoting chronic SASP inflammation, frailty, and paradoxically late-life cancer in old age.
  • Bret S. Weinstein & Deborah Ciszek (2002) (Experimental Gerontology, “The reserve-capacity hypothesis”): Explicitly cast the telomeric fail-safe (short telomeres / repressed somatic telomerase) as “an evolved antagonistic pleiotropy” trading tumor suppression against tissue repair capacity.
  • Abraham Aviv, Jerry W. Shay & Woodring E. Wright (e.g., Stone et al., 2016, PLOS Genetics, “Telomere Length and the Cancer–Atherosclerosis Trade-Off”; Aviv & Shay, 2018): Framed human short telomeres and repressed telomerase as an evolutionary trade-off between cancer and degenerative vascular disease.
  • Steven N. Austad & Jessica M. Hoffman (2018) (Evol. Med. Public Health, “Is antagonistic pleiotropy ubiquitous in aging biology?”): Treat almost any lifespan-extending knockout with an early-life fitness or reproduction penalty (daf-2, age-1, chico, p66shc, Ames/Snell dwarfs) as AP.
  • Alexey Golubev, Andrew Hanson & Vadim Gladyshev (2018) (Antioxidants & Redox Signaling, “A Tale of Two Concepts”): Explicitly wrote that AP theory has been “mistaking a cumulative quantitative process for a qualitative switch”—and argued that lifelong reactive metabolites (like ROS from NOX enzymes or glycation) whose collateral damage slowly builds up over decades should be treated as AP.
  • David Gems & Carina Kern (2024) (Ageing Research Reviews): Explicitly expand AP beyond sign-flipping developmental “quasi-programs” to include synchronous “firehose-type costly programs” (e.g., neutrophils defending against acute infection while causing cumulative collateral lung elastin destruction leading to COPD).

Who already called out this exact drift (and criticized calling tumor suppression/telomeres AP):

The user’s critique matches a very specific rebel camp in biogerontology:

  • Aubrey de Grey (e.g., 2015 FoundMyFitness discussion with Rhonda Patrick): Made almost the exact argument in your quote about inflammation and GH/IGF-1—saying these aren’t strictly AP (“good in the young, bad in the old”), but rather “good in the old and bad in the old in different ways,” where turning up inflammation or turning down GH still carries a live cost/benefit trade-off within old age.
  • Mikhail V. Blagosklonny (2010) (Cell Cycle, “Revisiting the antagonistic pleiotropy theory of aging”): Explicitly attacked p53 / tumor suppression as a fake example of AP: “neither p53-null nor p53+/- mice live longer. In contrast, loss of p53 shortens life span, by shifting age-related pathology (namely, cancer) earlier in life… p53 could be even viewed as an anti-aging gene.” Blagosklonny insisted true AP applies to developmental/growth run-on pathways like mTOR (essential early, purely destructive “quasi-program” late).
  • Stefano Giaimo & Fabrizio d’Adda di Fagagna (2012) (Aging Cell, “Is cellular senescence an example of antagonistic pleiotropy?”): Directly challenged Campisi’s consensus, arguing there is little evidence that cellular senescence’s net fitness effect is positive in youth and flips negative in old age—tumor suppression remains vital throughout life.
  • Axel Kowald, João Passos & Thomas Kirkwood (2020) (Aging Cell, “On the evolution of cellular senescence”): Also rejected the simple AP-anti-cancer story, arguing cellular senescence evolved for transient tissue remodeling/wound healing and accumulates later due to imperfect immune clearance (a false-positive vs. false-negative detection trade-off).
  • Alexei Maklakov & Tracey Chapman (2019) (Proc. R. Soc. B, “Evolution of ageing as a tangle of trade-offs: energy versus function”): Sharply separated continuous energy/maintenance trade-offs (DST) from age-specific functional trade-offs (Developmental Theory of Aging, citing Andrew Dillin et al., 2002, who showed knocking down daf-2after maturity in C. elegans extends lifespan with zero early reproductive cost, and Marina Ezcurra et al., 2018, showing gut-to-yolk conversion becomes pure self-digestion post-reproduction).
  • Samuel Pavard & C.J.E. Metcalf (2024) (Human Evolutionary Demography): Highlighted that telomere shortening/telomerase repression is really a trade-off between competing causes of mortality (cancer vs. tissue/organ failure) rather than a simple early-good/late-bad switch.

3. Sanity-Checking the Two Examples

A. “Like the horns of a ram that if grown too large will pierce its own skull… Remove horns from an old [ram] and it will live many more years.”

  • Biological caveat: In wild rams (like Rocky Mountain bighorn sheep), continuous horn growth rarely kills the animal by piercing its skull because wild rams naturally “broom” (splinter and wear down) the tips on rocks once they curl past the eyes. Actual cases of horns growing into the eye, cheek, or frontal bone occur overwhelmingly in unmanaged domestic/captive sheep and cattle (where veterinary welfare studies document ingrown horns). The textbook wild example of a sexual ornament growing backward into its own skull is the babirusa (Babyrousa, an Indonesian wild pig whose upper canines pierce its snout and can puncture the skull if not worn down).
  • Conceptual caveat: Even here, it’s only the unstoppable growth rate (the missing off-switch) that flips sign; removing all horns from a wild ram would still hurt his dominance/reproduction, whereas trimming only the ingrown tip removes the run-on cost. (Cleaner pure sign-flippers in biology are Williams’s arterial calcification, presbyopia, or post-reproductive C. elegans yolk production.)

B. “Extend all telomeres of an old person and they will soon die of cancer”

This is overstated as a flat biological fact, though it captures a real human evolutionary constraint:

  • What supports the quote: In humans, Mendelian randomization studies (Telomeres MR Collaboration, 2017; Codd et al., 2021) consistently find that genetically longer telomeres increase risk of many cancers (glioma, lung adenocarcinoma, melanoma, thyroid, kidney) while reducing cardiovascular/atherosclerosis risk. Likewise, DeBoy et al. (2023) (NEJM) showed that humans with germline POT1 mutations (“long telomere syndrome,” ~90% longer telomeres) display some delayed aging traits like slower graying alongside high rates of clonal hematopoiesis, melanoma, and other neoplasms. Permanently unlocking telomerase in every cell of a 75-year-old human—whose tissues already harbor decades of pre-oncogenic mutations—is widely considered high-risk for cancer.
  • What contradicts “they will soon die of cancer”:
    1. Empirical animal tests went the other way:Maria Blasco’s lab (Bernardes de Jesus et al., 2012, EMBO Mol. Med.) treated 1- and 2-year-old mice with transient AAV9-mTERT telomerase gene therapy; it extended median lifespan by 24% and 13% without increasing cancer (similarly in Zhu et al., 2024, Aging Cell). Caveat: Lab mice are small, short-lived, and already have ultra-long telomeres—which is Weinstein & Ciszek’s (2002) exact criticism of mouse models.
    2. Short telomeres also cause cancer in old age: Critically short, uncapped telomeres trigger chromosome end-to-end fusions, genomic instability, and SASP-driven tumor-promoting inflammation, while weakening immune T-cell clearance of tumors. So keeping telomeres short in old age isn’t purely protective either—it is genuinely double-edged even late in life.

Bottom Line

The quote’s core philosophical diagnosis is spot-on: aging literature routinely lumps diachronic sign-flippers (early adaptation pure late-life pathology you can safely turn off) together with ongoing, live trade-offs (like telomerase silencing, inflammation, or energy allocation) where turning the mechanism off in old age still re-exposes you to the original hazard. If you want a clean historical summary: Williams (1957) leaned toward sign-flipping developmental run-on, Rose (1982) defined the term “antagonistic pleiotropy” broadly enough to cover any fitness-component trade-off, and Blagosklonny (2010), Giaimo & d’Adda di Fagagna (2012), Aubrey de Grey (2015), and Maklakov & Chapman (2019) have all explicitly called out the resulting confusion.